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Abstract
Background: The Drug Ontology (DrOn) is an OWL2-based representation of drug products and their ingredients,
mechanisms of action, strengths, and dose forms. We originally created DrOn for use cases in comparative effectiveness
research, primarily to identify historically complete sets of United States National Drug Codes (NDCs) that represent
packaged drug products, by the ingredient(s), mechanism(s) of action, and so on contained in those products. Although
we had designed DrOn from the outset to carefully distinguish those entities that have a therapeutic indication from
those entities that have a molecular mechanism of action, we had not previously represented in DrOn any particular
therapeutic indication.
Results: In this work, we add therapeutic indications for three research use cases: resistant hypertension, malaria, and
opioid abuse research. We also added mechanisms of action for opioid analgesics and added 108 classes representing
drug products in response to a large term request from the Program for Resistance, Immunology, Surveillance and
Modeling of Malaria in Uganda (PRISM) project. The net result is a new version of DrOn, current to May 2016, that
represents three major therapeutic classes of drugs and six new mechanisms of action.
Conclusions: A therapeutic indication of a drug product is represented as a therapeutic function in DrOn. Adverse
effects of drug products, as well as other therapeutic uses for which the drug product was not designed are dispositions.
Our work provides a framework for representing additional therapeutic indications, adverse effects, and uses of drug
products beyond their design. Our work also validated our past modeling decisions for specific types of mechanisms of
action, namely effects mediated via receptor and/or enzyme binding. DrOn is available at: http://purl.obolibrary.org/obo/
dron.owl. A smaller version without NDCs is available at: http://purl.obolibrary.org/obo/dron/dron-lite.owl
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Background
The Drug Ontology (DrOn) is a Web Ontology Language
version 2 (OWL2) based representation of drug products
and their ingredients, mechanisms of action, strengths,
and dose forms, as well as packaged drug products as rep-
resented by United States National Drug Codes (NDCs)
[1–3]. The primary goal of DrOn is to support analyses of
large, drug-related datasets such as pharmacy claims and
electronic health record (EHR) data. Pharmacy claims
datasets have traditionally been available to researchers
from public and private payers (or third-parties that serve
as the gateway to those payers’ data). In addition, state-
wide prescription drug monitoring programs to combat
opioid abuse are increasingly objects of study and capture
NDCs of packaged drug products. These datasets use
NDCs to identify the specific drug product that was dis-
pensed to the patient as well as the drug product’s pack-
aging and manufacturer. With the advent of research
consortia and networks such as the Observational Health
Data Sciences (OHDSI) collaborative [4] and the National
Patient Centered Clinical Research Network (PCORnet)
[5], massive EHR data sets with prescribing records nor-
malized to the RxNorm terminology are increasingly avail-
able to researchers. RxNorm is a standard medication
terminology built by the National Library of Medicine to
standardize prescribing data [6].
Research using these increasingly available and growing
claims and EHR datasets is facilitated by the ability to query
their drug data based on various characteristics of the drug
product prescribed or dispensed, such as therapeutic indi-
cation (e.g. hypertension) or mechanism of action of an ac-
tive ingredient (e.g. beta blocker), rather than on the drug
product itself. But the prototypical prescribing record in an
EHR dataset identifies the drug product at the level of in-
gredient, dosage, and dose form—for example, furosemide
20 mg oral tablet—using a concept unique identifier from
RxNorm (i.e., RxCui). The prototypical dispensing record
in a claims database and prescription drug monitoring data-
base uses an NDC to identify the drug product and its
manufacturer and packaging: for example, a bottle of 100
furosemide 20 mg oral tablets from Sanofi-Aventis branded
as Lasix. In the former case, the prescribing record will typ-
ically have an RxCui of 310429 for the furosemide 20 mg
tablet. In the latter case, the dispensing record will typically
have an NDC of 00039006710 for a bottle of 100 tablets.
To query prescribing and/or dispensing records for all anti-
hypertensives—or for all products with a beta-blocker as an
ingredient—the researcher needs an easy way to generate
lists of all RxCuis and/or NDCs, respectively, that represent
drug products with these characteristics. Our goal in creat-
ing DrOn was to create this ability.
Artifacts that pre-existed DrOn were not sufficient
for our purposes for various reasons. For example,
any given version of RxNorm only contains the NDCs
that were active at the time the version was released,
but DrOn contains a historical record of NDCs.
RxNorm, therefore cannot support querying historical
EHR and claims datasets spanning multiple years and
sometimes even decades without significant process-
ing of past versions. This is not to criticize RxNorm:
its primary use case was to support prescribing and
ordering of medications in a clinical setting (and
hence its central focus is the so-called Semantic Clin-
ical Drug). In addition, RxNorm is not available as an
OWL2 artifact to support integration with other on-
tologies such as those available from the Open Bio-
medical and Biological Ontology Foundry [7]. Unlike
RxNorm and all other OWL2 artifacts of which we
are aware, DrOn also represents the binding of ingre-
dient compounds to cytochrome P450 (CYP) isoen-
zymes as either substrate, inhibitor, or both to
support research on potential drug-drug interactions
[1]. Lastly, although the National Drug File Reference
Terminology (NDF-RT) is another OWL2 artifact
with drug information such as therapeutic indications
and mechanisms of action, it (a) makes basic scien-
tific mistakes such as saying that ophthalmic timolol
may treat systemic hypertension and that oral vanco-
mycin may treat bacterial endocarditis and (b) has
not been updated in its OWL2 form since 2013.
The increasing applicability and relevance of DrOn
was the motivation for the work described here. Specific-
ally, there were three use-cases from three major
research-focused projects that included representing
anti-hypertensive, anti-malarial, and analgesic thera-
peutic indications of certain drug products.
Although we had designed DrOn from the outset to
avoid the scientific mistakes about therapeutic uses of
drugs made by NDF-RT and other artifacts, prior to this
work DrOn did not represent any particular therapeutic
indication(s) of drug products. Furthermore, the use case
motivating analgesic indications also required represent-
ing the mechanisms of action of opioid analgesics and
antagonists, which we describe here. Also, the project
motivating inclusion of information about which drug
products are anti-malarials submitted a request for a
large number of terms that resulted in additional signifi-
cant development of DrOn that we report here. Lastly,
we illustrate for the first time a method for querying
DrOn to generate sets of RxCuis and/or NDCs to meet
the use cases driving DrOn development.
Methods
We first present the three research projects and the use
cases that they presented. Then we describe our meth-
odology for addressing the use cases. Lastly, we discuss a
software tool that we developed and used to query sets
of RxCuis or NDCs from DrOn.
Hogan et al. Journal of Biomedical Semantics  (2017) 8:10 Page 2 of 11
Use cases
OneFlorida clinical data research network
The OneFlorida Clinical Research Consortium is a state-
wide infrastructure in Florida for implementation science,
comparative effectiveness research, and pragmatic clinical
trials [8]. It applied for and was awarded Phase II funding
as a Clinical Data Research Network (CDRN) in the Na-
tional Patient Centered Clinical Research Network (PCOR-
net). As part of PCORnet, OneFlorida is required to
develop a patient cohort around a common condition, for
which it chose hypertension [8].
Computable phenotypes are commonly used to identify a
subpopulation of interest [9]. In particular, researchers in
OneFlorida are studying resistant hypertension. Develop-
ment of the resistant hypertension cohort requires ex-
tremely accurate counting of how many anti-hypertensives
a patient is taking. To support the development of accurate
computable phenotypes for hypertension that, for example,
do not categorize patients as having hypertension who are
receiving ophthalmic timolol but no anti-hypertensive drug,
it was necessary to represent hypertension in DrOn as a
therapeutic indication of drug products rather than of mo-
lecular compounds. Because the OneFlorida data warehou-
se—called the OneFlorida Data Trust—incorporates both
claims and EHR data, it is necessary to query for lists of
both NDCs and RxCuis which are used to standardize EHR
data to identify the drug product prescribed (at the pre-
scription stage, which manufacturer and packaging are not
known or even typically specified). In DrOn, a drug product
is a tablet, capsule, portion of solution, portion of cream,
etc. (prescription) whereas a packaged drug product is a
bottle of tablets or capsules, a tube of cream, a vial of solu-
tion, etc. for sale, distribution, delivery to the hospital ward
from the pharmacy, etc. (dispensing). Figure 1 shows the re-
lationships among packaged drug products, drug products,
and ingredients as captured in DrOn.
Program for Resistance, Immunology, Surveillance and
Modeling of Malaria (PRISM)
The Program for Resistance, Immunology, Surveillance and
Modeling of Malaria in Uganda (PRISM) is an International
Center of Excellence for Malaria Research (ICEMR) that
serves East Africa. It is a collaboration between Makerere
University in Uganda and the University of California San
Francisco. The National Institute for Allergy and Infectious
Disease (NIAID) created the ICEMR program in 2010 to
establish a worldwide network of research centers in
malaria-endemic settings to develop infrastructure for
researchers and practitioners working in various settings,
especially governments and healthcare institutions, to
combat malaria.
PRISM required representing anti-malarial indications of
drug products. It also submitted a request for a large num-
ber of terms to support matching drug codes in various
data sets to DrOn. Upon cursory review, it appeared that
many of these requests matched classes already in DrOn.
However, after discussion it became apparent that PRISM
required semantics for their requests that differed from the
classes that we created in DrOn to match RxNorm. Specif-
ically, RxNorm semantic clinical drugs (e.g. amoxicillin
50 mg/mL oral suspension) and semantic clinical drug
forms (e.g. amoxicillin oral suspension) list all active ingre-
dients exhaustively in a drug product—that is, they pre-
clude the possibility of having additional active ingredients.
For example, the class amoxicillin oral suspension does not
subsume the class amoxicillin/clavulanate oral suspension,
because it cannot have (by definition) additional active in-
gredients besides amoxicillin. The consequence is that in
RxNorm (and therefore in DrOn) amoxicillin oral suspen-
sion is a sibling—not a parent—of amoxicillin/clavulanate
oral suspension. Other combination drug suspensions with
amoxicillin are also siblings. In addition, there is no com-
mon parent in RxNorm or DrOn for these drug products
(i.e., there is no class amoxicillin-containing suspension as a
common parent to the numerous siblings). However,
PRISM required classes that had the semantics of amoxicil-
lin-containing suspension that subsumes all kinds of sus-
pensions containing amoxicillin (both with and without
other active ingredients).
Prescription drug monitoring program research
Prescription Drug Monitoring Programs (PDMPs) such as
Florida’s Electronic-Florida Online Reporting of Controlled
Substance Evaluation Program (E-FORCSE®) [10] utilize
Fig. 1 Representation of packaged drug products, drug products, ingredients, and the relationships among them in DrOn
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databases of prescribed, controlled medications that include
limited patient information, prescriber information, and
NDCs for the dispensed medication. These databases may
be accessed by prescribers (to view their prescribing histor-
ies), pharmacists, and law enforcement. Health researchers
may also utilize this information to monitor (1) the intro-
duction of newly controlled substances on the market, (2)
medical morphine exposure in high-risk patient popula-
tions, (3) multi-drug prescribing associated with overdose
(e.g. overlapping prescriptions of opioids and benzodiaze-
pines), and (4) the impact of opioid prescribing policies
(e.g. on reducing prescribing of short-acting formulations
as the first option) on real-world prescribing behavior.
Opioid research with the PDMPs required the ability to
query opioid analgesics based on (1) a combination of
therapeutic indication (pain, medication assisted therapy
for opioid dependence) and mechanism of action (binding
to opioid receptors), (2) different mechanisms of action,
specifically binding to mu, delta, and/or kappa opioid re-
ceptors in either antagonistic or synergistic ways, and (3)
whether a drug is short- or long-acting. These queries are
important to pharmacoepidemiologists for understanding
the abuse potential and addictive properties of drug
products.
Methodology of DrOn development
Hogan et al. [3] and Hanna et al. [1, 2] describe our
methods of developing DrOn. DrOn development occurs
in two major parallel processes. The first process is trad-
itional, manual editing using the Protégé ontology editor.
We add to DrOn all information about the therapeutic
indications and mechanisms of action of drug products
and their ingredients through this manual process: we
do not automatically import it from any other source.
As described below, we search numerous sources of in-
formation to develop a comprehensive list of drug prod-
ucts with a particular indication or ingredients with a
particular mechanism of action, and we then curate the
information manually using Protégé. The second process
involved in building DrOn is automated construction of
classes from RxNorm.
DrOn is an OBO ontology and follows the OBO Foun-
dry’s realist methods and principles of ontology develop-
ment [7]. The ability to avoid confusing ophthalmic timolol
as an anti-hypertensive and oral vancomycin as having any
efficacy whatsoever against bacterial endocarditis was a key
validation of the realist approach we took in [3]. This ability
was the result of a key insight from our realist analysis that
a therapeutic indication is a property of a drug product
(tablet, ointment, cream, solution, etc.) with one or more
active ingredients; whereas the mechanism of action is typ-
ically the property of a chemical compound (Fig. 2). For ex-
ample, a molecule of timolol has the capability to
competitively bind a beta-adrenergic receptor, but one
molecule by itself has no ability to treat hypertension; it re-
quires instead a number of timolol molecules on the order
of Avogadro’s number to lower blood pressure. The drug
product, therefore, has a sufficient number of molecules, as
well as a formulation, that can be targeted towards a spe-
cific indication or indications. Thus, a timolol oral tablet
drug product has the indication of hypertension (but not
glaucoma); a portion of timolol ophthalmic solution has the
indication of glaucoma (but not hypertension); and one
timolol molecule by itself has no indication.
Besides dose form and intended route(s) of administra-
tion, the strength (quantity of active ingredient(s)) of a
drug product also affects its therapeutic indication. For
example, finasteride is prescribed in 5 mg dosages to
treat benign prostatic hyperplasia but in 1 mg dosages to
treat androgenetic alopecia. This example further sup-
ports our claim that the drug product, not the molecule,
is the bearer of a therapeutic indication.
DrOn is available as both the full ontology, including
NDCs, and a version without NDCs that includes all the
manually edited content as well as content derived from
RxNorm and imported from the Chemical Entities of Bio-
logical Interest ontology (ChEBI), the Protein Ontology
(PRO), and other ontologies. This “lite” version of DrOn is
available at [11]. The reader who is interested in reprodu-
cing our results on reasoning (methods and results dis-
cussed below) will find this version most amenable to the
task. We recommend using the Fact++ reasoner in Pro-
tégé version 5.1, and adjusting the Java heap size to 2GB
or more (4GB is recommended).
Methods for representing therapeutic indications
We analyzed therapeutic indications according to the realist
perspective that we have maintained throughout the devel-
opment of DrOn. Based on Hogan et al. we had already de-
termined that a therapeutic indication is a property of a
drug product and thus is some subtype of specifically
dependent continuant per Basic Formal Ontology (BFO)
[3]. Our analysis in this work focused further on whether it
is more specifically a quality, role, or disposition, and if the
latter, whether it is more specifically a function.
Methods for representing opioid analgesic mechanisms of
action
Opioid-acting compounds primarily act by binding μ (mu),
κ (kappa), and δ (delta) opioid receptors (there are as many
as 17 kinds of opioid receptors in total). These receptors
are located in the cellular membranes of peripheral and
central nervous system neurons. The major effect of this
binding is to prevent the release of neurotransmitters at the
presynaptic nerve terminal, although opioid receptors also
exist at the postsynaptic neuron with inhibitory effects. The
consequent reduction in neurotransmission is what causes
analgesic effects as well as side effects (or sometimes even
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desired effects) such as decreased bowel motility leading to
constipation.
Authors SA, BB, RE, TM, and MV looked for lists of
compounds with opioid activity in various resources, each
one focusing on a particular resource. The resources we
searched included DrugBank, NDF-RT, BioPortal, Onto-
bee, ChEBI, Wikipedia, and Goodman and Gilman’s Man-
ual of Pharmacology and Therapeutics [12], as well as
general Internet searches using Google. Each person also
determined whether each compound on the list is used in
drug products for analgesic activity. Once each person
had generated as complete a list as she or he could from
her or his assigned resource, we deduplicated the lists to
produce a master list [13].
Once we had obtained a master list, the same authors
subsequently searched the same kinds of resources for
whether each compound was a mu agonist/antagonist,
kappa agonist/antagonist, and/or a delta agonist/antagon-
ist. Note that some compounds have agonist activity at
one receptor but antagonist activity at another receptor.
For example, fentanyl is a mu agonist and delta antagon-
ist, although in bulk its mu agonist effects dominate such
that it produces analgesia.
Methods for creating new classes
Authors SA, BB, MD, RE, TM, and MV each created
one subset of the requested OWL classes for the PRISM
project such that the union of these subsets covered all
the requests for which we could identify the active ingre-
dients. These six “class creators” created about 20 classes
each. To avoid conflicts in the DrOn git repository on
BitBucket, author JH created a fork of the repository
called dron-workspace. Authors WRH and AH then set
up a separate OWL file for each “class creator”. This
allowed each one to check in his or her OWL file with-
out any need for a merger that could break the RDF/
XML in any OWL file. If another “class creator” had
checked in his or her file before, synchronization was
easily achieved by doing a “git pull” command before is-
suing a “git push” to the centralized repository. Finally,
author JH merged the results of all six OWL files into a
new dron-hand.owl module of DrOn.
For one group of term requests, route of administra-
tion was applicable. This group of terms involved drug
solutions (i.e., one or more active ingredients dissolved
in a liquid medium). Some drug solutions are designed
for intravenous administration; some are designed for
both ophthalmic and otic adminstration (i.e., one formu-
lation can be administered either way); and some are
formulated only for ophthalmic administration. We have
not yet represented routes of administration of drug
products in DrOn; this task is out of the scope of this
paper and remains for future work. For drug solution
terms, we created a generic “solution class” with an
equivalent class definition. As an example, we define
gentamicin solution as:
‘drug solution’ and (has_proper_part
some (‘scattered molecular aggregate’
and (‘is bearer of’ some ‘active
ingredient role’)
and (‘has granular part’ some
gentamicin)))
Then we created classes gentamicin intravenous solu-
tion and gentamicin ophthalmic solution as primitive
children of the gentamicin solution class.
Software tool for querying DrOn
To query sets of RxCuis or NDCs from DrOn for use in
research with EHR and claims datasets, we developed
dron-query, an open-source, Java-based, command-line
software application that uses the pre-existing OWL-API
(Web Ontology Language Application Programming
Interface) library. The dron-query application is available
on GitHub at [14], and there is a getting started Wiki
page at [15]. Essentially, dron-query (1) takes as input a
description logic (DL) query formatted in Manchester
Syntax (a standard syntax for writing description logic
axioms in Protégé among others), (2) executes it using a
description-logic reasoner, and (3) outputs for every
class that meets the criteria specified in the query its (a)
IRI, (b) rdfs:label, and (c) RxCui annotation value. If the
Fig. 2 Representation of molecular dispositions to capture mechanisms of action in DrOn
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query is for packaged drug products, the NDC is the
rdfs:label output for the class, and the RxCui field in the
output is null. But if the query is for drug products, the
RxCui field is populated in addition to the IRI and
rdfs:label.
We developed and executed DL queries using dron-
query for the three use cases, and report the results.
Results
We represented (1) anti-malarial function and asserted it
as a function of 57 drug products (the reasoner infers it
to be a function of an additional 203 drug products), (2)
anti-hypertensive function and asserted it as a function
of 326 drug products (inferred for 2419 additional prod-
ucts), (3) analgesic function and asserted it as a function
of 413 drug products (inferred for 2779 additional prod-
ucts), and (4) six opioid mechanisms of action and
asserted them as dispositions of 59 chemical com-
pounds. We created 108 new classes in response to the
PRISM term request.
Therapeutic indications
A drug product has the potential to treat a disease or
symptom or other condition, and this potential is only
realized upon administration of the product to—and
subsequent action on—an organism. Note that here we
are using the word ‘potential’ in the sense of an ability
or capability and not in the sense of probability of the
ability or capability of being realized.
Administering a drug product does not guarantee
realization of this potential; for example, one dose might
be insufficient, or edema of the bowel wall might inhibit
absorption of the drug, or the patient might have a
genotype that results in excessive metabolism of the ac-
tive ingredient into an inactive metabolite.
According to Basic Formal Ontology, this situation
means that a therapeutic indication of a drug product is
a realizable entity or one of its subtypes. BFO defines
‘realizable entity’ as …a specifically dependent continuant
that has at least one independent continuant entity as its
bearer, and whose instances can be realized (manifested,
actualized, executed) in associated processes of specific
correlated types in which the bearer participates [16].
Furthermore, because the physical makeup of the
drug product confers this potential, and because
physical changes to the drug product can cause it to
lose its ability to treat instances of a particular type
of symptom or disease, a therapeutic indication is a
disposition (a subtype of realizable entity). BFO de-
fines ‘disposition’ as a realizable entity that is such
that, if it ceases to exist, then its bearer is physically
changed [16]. Drug products can only lose their
therapeutic potential through physical change. For ex-
ample, a portion of epinephrine solution contained in
a self-injection device degrades upon exposure to air
and light, diminishing and ultimately removing with
time its disposition to treat hypersensitivity reactions.
Lastly, for a therapeutic indication of a drug product for
which the product was intentionally manufactured, a
therapeutic indication is a function, which per BFO is a
kind of disposition. BFO defines ‘function’ as …disposition
that exists in virtue of the bearer’s physical make-up, and
this physical make-up is something the bearer possesses be-
cause of how it came into being—either through natural se-
lection (in the case of biological entities) or through
intentional design (in the case of artifacts) [16]. Because
drug products are extensively designed and planned to
have certain therapeutic indications, these indications are
functions. We also note that this usage is consistent with
the most recent exposition of functions as they are repre-
sented by BFO [17]. Figure 3 illustrates the relationship of
drug products to therapeutic functions.
Note that this means that given the definitions of ‘func-
tion’ and ‘disposition’ in BFO, the therapeutic potential(s)
of a drug product for which the product was manufac-
tured are functions, whereas therapeutic uses that are dis-
covered later (for example, “off label” uses of a drug per
the Food and Drug Administration) are initially disposi-
tions that are not functions. Should the manufacturer sub-
sequently manufacture the product with the intention of
including these additional therapeutic indications, then
these potentials are functions.
Note, however, that no particular instance of disposition
becomes an instance of function. For example, consider a
drug product that is a tablet with an indication (function)
“to treat X.” Suppose that later researchers discover that
the tablet also has the disposition “to treat Y.” Then all the
tablets manufactured prior to the addition of this indication
bear a function “to treat X” and a disposition “to treat Y”,
whereas all the tablets manufactured after the change bear
two functions: “to treat X” and “to treat Y.” It is possible
that the exact same physical basis for the disposition exists
for the function. This is analogous to the chopsticks ex-
ample of Spear et al. where there are two identical sticks of
wood (in terms of structure and form) one with the func-
tion “to handle food” because it was designed and manufac-
tured to handle food, and one with a disposition but not a
function “to handle food” because it came to have its struc-
ture incidentally [17].
Therefore, a therapeutic indication (function) is a sub-
type of therapeutic potential (disposition), where the
Fig. 3 A drug product is the bearer of a therapeutic function
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former is the result of an intensively planned and exe-
cuted manufacturing process and the latter is broader
and includes effects of drug products that are discovered
after they are manufactured. For example, bupropion
tablets were originally designed and manufactured for
depression. Later, researchers discovered that they also
helped with smoking cessation, so companies started
manufacturing these tablets for smoking cessation in
addition to depression, ergo a new therapeutic function.
Bupropion tablets manufactured prior to the change
have one function; bupropion tablets manufactured after
the change have two functions.
This distinction also helps to differentiate thera-
peutic indications from adverse effects of drug prod-
ucts. The realization of a disposition of an oxycodone
tablet to cause constipation is an undesired effect. It
is not a therapeutic indication (function). The dispos-
ition of oxycodone tablets to create a dependence (or
addiction) is also an adverse event. We would repre-
sent in DrOn the dispositions to adverse events. Per
the Ontology of Adverse Events (OAE), an adverse
event is a process [18]. This process is typically the
realization of certain dispositions of the drug product.
Thus, we have also identified a key way to link DrOn
to OAE: a disposition of a drug product (DrOn) is re-
alized by an adverse event process (OAE).
In some cases, a type of disposition can have some
instances whose realizations are therapeutic and other
instances whose realizations are adverse events. For
example, erythromycin when used to treat infection
can have the adverse event of diarrhea caused by its
disposition to increase gastric motility. However, the
same disposition to increase gastric motility is some-
times used therapeutically to treat gastroparesis
caused by diabetes mellitus. In other cases, the type
of disposition can have some instances whose realiza-
tions are both therapeutic effects and adverse events,
such as when the therapeutic effect is taken to an ex-
treme (e.g., bleeding from anti-coagulant therapy and
hypotension from anti-hypertensive therapy).
Anti-hypertensive therapeutic function
Def: a therapeutic function of a drug product that is re-
alized by administration of the drug product resulting in
a decrease of systemic arterial pressure.
Hypertension is a sustained elevation in the pressure
exerted by blood on the systemic arteries (as opposed to
pulmonary arteries) of an organism. This condition is
well known to be a risk for multiple morbidities includ-
ing coronary artery disease, stroke, and kidney disease.
Drug products manufactured to treat hypertension all
have the disposition of lowering this pressure when ad-
ministered in the proper form and according to the
proper route of administration.
Anti-malarial therapeutic function
Def: a therapeutic function of a drug product that is re-
alized by administration of the drug product resulting in
creation of a material basis of a resistance to malaria in-
fection disposition.
In other words, a drug product like a choloroquine
tablet confers upon administration a protective resist-
ance to an infection of a certain kind, namely protective
resistance to individuals of one of four Plasmodium spe-
cies. The Infectious Disease Ontology defines ‘protective
resistance’ as: A disposition that inheres in a material
entity in virtue of the fact that the entity has a part (e.g.
a gene product), which itself has a disposition to mitigate
damage to the entity [19]. Resistance to an infectious
agent then is a type of protective resistance. This kind of
resistance can be either acquired or innate (e.g., an ex-
treme but common case of innate resistance is the resist-
ance of one species to the infectious agents that
commonly infect another species). Acquired resistance
can occur through acquired immunity, through adminis-
tration of anti-infective drug products, and through
other mechanisms.
An anti-malarial is thus a drug product that, when ad-
ministered, confers a protective resistance to humans
against the four species of Plasmodium that cause mal-
aria in humans. DrOn imports ‘resistance to malaria in-
fection’, which is itself defined as A resistance to infection
by P. vivax, P. ovale, P. malariae, and/or P. falciparum.
Analgesic therapeutic function
Def: a therapeutic function of a drug product that is re-
alized by administration of the drug product resulting in
blocked realization of a disposition to pain.
We follow the definition of ‘pain’ by Smith and Ceus-
ters as a type of process: an unpleasant experience on
the part of a human subject that is both sensory and
emotional and that is of a type that is either canonical
pain … or phenomenologically indistinguishable from ca-
nonical pain [20]. The physical basis of the pain can
range from activation of the nociceptive system (canon-
ical pain) to damage to the nociceptive system (neuro-
pathic pain) to changes in the cognitive system (e.g.,
pain behavior without nociception).
The net result is that certain physical changes result in
a disposition to experience pain, and the ultimate effect
of analgesics is to block the realization of this dispos-
ition. Restated, they confer a blocking disposition to pain
dispositions.
Adding mechanisms of action for opioid analgesics
We defined six dispositions, all of which inhere in mole-
cules. There are two each (agonistic and antagonistic)
for each of the three major opioid receptors that were
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relevant to the E-FORCSE use case. These definitions all
follow the template:
A disposition of a molecule to bind an instance of <
kind of receptor > in a manner that < activates,
inhibits > the realization of the biological function of
the receptor.
We then link the function to the molecule using
OWL2 axioms of the form:
<molecule> subClassOf (‘is bearer of’
some <disposition>)
(where ‘is bearer of ’ is an object property, <molecule >
is a class, and < disposition > is a class).
Note that for compounds in DrOn that are repre-
sented by ChEBI class internationalized resource iden-
tifiers (IRIs), we are asserting this axiom directly on
ChEBI classes (which is true of nearly all the opioid
compounds). Furthermore, we note that we do not
yet represent in DrOn the processes that realize these
dispositions, nor the other participants in these pro-
cesses (e.g., the mu receptor itself ). The reason is that
our use cases have not yet required it. However, we
acknowledge that it might be useful to query for all
drug products whose ingredients act on mu receptors,
regardless of whether the action inhibits or activates
the receptor. It therefore remains future work to
enhance the representation in DrOn to include the
processes that realize molecular dispositions and their
participants. We note that the Gene Ontology [21]
has terms for the processes (e.g., GO:0031698 beta-2
adrenergic receptor binding), and the Protein
Ontology [22] has terms for the receptors (e.g.,
PR:000001193 beta-2 adrenergic receptor) that should
be reused for this purpose. For more on DrOn’s rep-
resentation of drug ingredients (molecules and aggre-
gates of them) and their dispositions and roles, see
Hanna et al. [1].
All told, we added at least one of the six dispositions
to 59 molecule types (Table 1).
We note that not all drug products with (an ingredient
that has) an opioid agonist mechanism have an analgesic
indication. For example, loperamide tablets are used to
treat diarrhea and are not indicated for pain relief (be-
cause they bind opioid receptors in the nerve cells of the
gut almost exclusively).
PRISM term request
We added 108 classes in response to the PRISM term
request: 89 classes have an equivalent class axiom, and
19 drug solution classes have necessary axioms only.
Figure 4 shows the class amoxicillin suspension and that
the Fact++ reasoner has inferred that the 10 amoxicillin
suspension classes (that derive from RxNorm) are sub-
sumed under it.
Using dron-query tool for the use cases
Anti-hypertensive query
We used dron-query to query several lists of RxCuis for
the anti-hypertensive use case. Specifically, we queried
all the RxCuis for anti-hypertensive products whose in-
gredients had one of the following mechanisms of ac-
tion, with one set of RxCuis per mechanism of action:
beta-adrenergic blockade, calcium channel blockade,
NKCC2 inhibition (loop diuretics), sodium-chloride co-
transporter inhibition (thiazide and thiazide-like di-
uretics), angiotensin converting enzyme inhibition, and
angiotensin receptor blockade.
The template for each query in Manchester syntax was
the following:
'drug product' and ('is bearer of' some
'anti-hypertensive function') and
(has_proper_part some ('has granular
part' some ('is bearer of' some
<disposition to bind some enzyme/
receptor>)))
Table 1 Counts of molecules with various opioid mechanisms
of action
Action Type of receptor
mu kappa delta
Agonist 28 11 9
Antagonist 4 3 3
Fig. 4 The new class amoxicillin suspension and its inferred children
in DrOn
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For beta blockers, the exact query is:
'drug product' and ('is bearer of' some
'anti-hypertensive function') and
(has_proper_part some ('has granular
part' some ('is bearer of' some 'non-
activating competitive beta-adrenergic
receptor binding disposition')))
This query returns 612 classes representing drug prod-
ucts at multiple levels of granularity (i.e., metoprolol oral
tablet, metoprolol 50 mg oral tablet, Lopressor 50 mg
oral tablet).
To get a set of NDCs for anti-hypertensive drug prod-
ucts with beta blocker ingredients, the query is:
‘packaged drug product’ and
(has_proper_part some ('is bearer of'
some 'anti-hypertensive function') and
(has_proper_part some ('has granular
part' some ('is bearer of' some 'non-
activating competitive beta-adrenergic
receptor binding disposition'))))
This query returns 4,831 classes and their NDCs.
Anti-malarial query
For all drug products with an anti-malarial function, the
query is:
'drug product' and ('is bearer of' some
‘anti-malarial function’)
This query returns 260 drug products and their
RxCuis.
Opioid analgesic query
For all analgesics that have a mu agonist as an ingredi-
ent, the query is:
'drug product' and ('is bearer of' some
analgesic) and (has_proper_part some
('has granular part' some ('is bearer of'
some 'mu agonist')))
This query returns 3034 drug products and their
RxCuis. The analogous query for packaged drug prod-
ucts (not shown) returns 8142 packaged drug products
and their NDCs.
Discussion
Based on use cases from three research projects, we ex-
tended DrOn with three therapeutic functions and six
mechanisms of action of drug products. We also added
108 classes in response to term requests, including amoxi-
cillin suspension and chloroquine tablet. These classes
have different semantics than RxNorm classes because
they do not exhaustively list all active ingredients. For ex-
ample, the new class amoxicillin suspension subsumes all
suspensions that have amoxicillin as one ingredient, in-
cluding compound drug products such as amoxicillin/cla-
vulanate oral suspension. Lastly, we illustrated the use of
the dron-query software tool for the three use cases.
The three therapeutic functions—anti-hypertensive,
anti-malarial, and analgesic—are fairly diverse, providing
preliminary evidence that our approach is general. There
are no common biological pathways, or even organ sys-
tems, to hypertension, malaria, and pain. Although the
blood is involved with both hypertension and malaria,
the anti-hypertensive drugs all have a mechanism of ac-
tion that take place elsewhere (especially the kidneys,
where they bind cellular receptors).
We have laid an ontological basis for representing add-
itional therapeutic indications, off-label usages, and adverse
effects of drug products. And per the original design of
DrOn, we capture the therapeutic indication on the appro-
priate entity (drug product and not molecule). In so doing,
we do not mistake ophthalmic timolol for an anti-
hypertensive or oral timolol for a glaucoma drug. Repre-
senting actual dispositions of drug products towards ad-
verse events, and thereby linking DrOn and OAE, remains
future work.
DrOn is extensible in the manner described for repre-
sentation of additional therapeutic functions. Ongoing
work at present includes representing the therapeutic
function to treat asthma.
In addition, our past approach to representing mecha-
nisms of action was in this work easily adapted to opiates
and opioids. However, we note that all the mechanisms of
action represented in DrOn to date involve drug molecules
binding to molecular entities in the cellular membrane (e.g.,
receptors, enzymes, and transporters). Representing mecha-
nisms of action that involve other kinds of processes might
not follow this pattern. For example, because anti-infectives
act on a symbiont of the organism to which they are ad-
ministered, as opposed to the organism itself, representing
them could be more complex. Nevertheless, the space of
compounds that exert a biological effect through receptor
binding and enzyme inhibition is large and diverse.
We do not at present relate the molecular mechanism(s)
of action of a molecule to the relevant therapeutic func-
tions of a drug product that incorporates the molecule, or
vice versa. Thus, for atenolol oral tablet there is no con-
nection between its function to treat hypertension and the
dispositions of its atenolol molecules to bind beta-
adrenergic receptors. This task is future work. Because
our representation does not require capturing the rela-
tionship between mechanisms of action and therapeutic
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functions however, we can represent in DrOn the thera-
peutic functions of drug products for which no mechan-
ism of action at the molecular level is yet known.
For the PDMP research, we have begun but not com-
pleted work on whether particular opiate and opioid-
containing drug products are short vs. long acting
formulations. We merely note here that duration of action
is a property of not just the half-life of the active ingredi-
ent(s) but also the particular way a dose is manufactured
(e.g., normal vs. delayed vs. extended release tablets and
capsules) and the genotype of the individual (e.g., single
nucleotide polymorphisms that result in poor vs. ultra-
rapid metabolism of drugs and prodrugs).
This work was limited to the extensions necessary to
meet specific research use cases. We have thus not stud-
ied clinical uses. However, we note that were a system
such as an EHR to recommend oral vancomycin to treat
endocarditis, or ophthalmic timolol to treat hyperten-
sion, a clinician might begin to doubt the system. In
addition, for our research use cases, we have not yet
compared counting anti-hypertensives, hypertensive pa-
tients, or patients with resistant hypertension using
DrOn to counting them using NDF-RT or other arti-
facts. This task remains as future work.
We also did not represent the intended routes of ad-
ministration of drug products, which prevented inclu-
sion of an equivalent class axiom on all classes added in
response to PRISM term requests. This task also re-
mains future work. We note that the Vaccine Ontology
has a set of classes representing routes of administration
that will likely be applicable [23].
We also note that none of the use cases discussed here
relate yet to pharmacogenomics or analyzing pharmaco-
dynamics or pharmacokinetics of drugs. However DrOn is
being used in other projects in this manner: we refer the in-
terested reader to Brochhausen et al. [24], which discusses
ontological representations of potential drug-drug interac-
tions and their pharmacodynamics and pharmacokinetics,
and how these representations reuse DrOn classes.
Conclusions
We successfully captured therapeutic indications of drug
products in the Drug Ontology as functions and other
therapeutic uses of drugs as dispositions, in keeping with
the definitions of ‘disposition’ and ‘function’ in Basic For-
mal Ontology. We represented the anti-hypertensive, anti-
malarial, and analgesic indications of numerous drug
products in DrOn in this manner. We also represented
the mechanisms of action of opioid analgesics (and other
opioid drug products), and we included over 100 new
classes in response to a term request from the PRISM pro-
ject. We also demonstrated how to use the dron-query
tool to extract from DrOn subsets of drug-product and
packaged-drug-product classes and their annotations for
various use cases. To date, our results show promise that
our methods are applicable to other therapeutic indica-
tions and mechanisms of action of drug products and
their ingredients, respectively.
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